Literature DB >> 32860531

Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center.

Eleonora Matteo1, Valentina Favoni2, Alessia Pascazio1, Umberto Pensato1, Matteo Benini1, Gian Maria Asioli1, Elena Merli1, Calogero Calabrò1, Pietro Cortelli1,2, Giulia Pierangeli1,2, Sabina Cevoli3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32860531     DOI： 10.1007/s10072-020-04667-0

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  8 in total

1.  Patient-reported outcomes of migraine treatment with erenumab: results from a national patient survey.

Authors:  Austėja Dapkutė; Jurgita Vainauskienė; Kristina Ryliškienė
Journal:  Neurol Sci       Date:  2022-01-10       Impact factor: 3.830

2.  Association between response to triptans and response to erenumab: real-life data.

Authors:  Ilaria Frattale; Valeria Caponnetto; Alfonsina Casalena; Maurizio Assetta; Maurizio Maddestra; Fabio Marzoli; Giannapia Affaitati; Maria Adele Giamberardino; Stefano Viola; Amleto Gabriele; Francesca Pistoia; Davide Cerone; Carmine Marini; Simona Sacco; Raffaele Ornello
Journal:  J Headache Pain       Date:  2021-01-06       Impact factor: 7.277

3.  Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany.

Authors:  Andreas Straube; Philipp Stude; Charly Gaul; Katrin Schuh; Mirja Koch
Journal:  J Headache Pain       Date:  2021-11-06       Impact factor: 7.277

Review 4.  Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes.

Authors:  Eleonora De Matteis; Simona Sacco; Raffaele Ornello
Journal:  Ther Clin Risk Manag       Date:  2022-04-05       Impact factor: 2.423

5.  Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.

Authors:  Luigi Francesco Iannone; Davide Fattori; Silvia Benemei; Alberto Chiarugi; Pierangelo Geppetti; Francesco De Cesaris
Journal:  CNS Drugs       Date:  2022-02-11       Impact factor: 5.749

Review 6.  Reducing the Burden of Migraine: Safety and Efficacy of CGRP Pathway-Targeted Preventive Treatments.

Authors:  George R Nissan; Richard Kim; Joshua M Cohen; Michael J Seminerio; Lynda J Krasenbaum; Karen Carr; Vincent Martin
Journal:  J Clin Med       Date:  2022-07-27       Impact factor: 4.964

7.  Clinic and genetic predictors in response to erenumab.

Authors:  Chiara Zecca; Sarah Cargnin; Christoph Schankin; Nadia Mariagrazia Giannantoni; Michele Viana; Isabella Maraffi; Gianna Carla Riccitelli; Shairin Sihabdeen; Salvatore Terrazzino; Claudio Gobbi
Journal:  Eur J Neurol       Date:  2022-01-21       Impact factor: 6.288

8.  MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention.

Authors:  Robert Belvís; Pablo Irimia; Patricia Pozo-Rosich; Carmen González-Oria; Antonio Cano; Javier Viguera; Belén Sánchez; Francisco Molina; Isabel Beltrán; Agustín Oterino; Elisa Cuadrado; Angel Gómez-Camello; Miguel Alberte-Woodward; Carmen Jurado; Teresa Oms; David Ezpeleta; Javier Díaz de Terán; Noemí Morollón; Germán Latorre; Marta Torres-Ferrús; Alicia Alpuente; Raquel Lamas; Carlos Toledano; Rogelio Leira; Sonia Santos; Margarita Sánchez Del Río
Journal:  J Headache Pain       Date:  2021-07-17       Impact factor: 7.277
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.